Loading...
Loading...
Merck
MRK, known as MSD outside the United States and Canada,
announced Saturday, the presentation of results from the company's Phase 3 C-EDGE
CO-STAR clinical trial evaluating the efficacy and safety of the
investigational once-daily tablet elbasvir/grazoprevir1
(50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes
(GT) 1, 4 or 6 infection who inject drugs and are receiving opioid
agonist therapy (OAT). Ninety-five percent (189/198) of patients treated
with elbasvir/grazoprevir for 12 weeks in the pre-specified primary
efficacy analysis population achieved sustained virologic response 12
weeks after the completion of treatment (SVR12, considered virologic
cure). Adherence to treatment was high, with 97 percent of patients
taking at least 95 percent of their study medication over the 12 weeks
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in